Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy

Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy

(2008) C. Li et al.   BLOOD

The largest prospective warfarin-treated cohort supports genetic forecasting

(2008) M. Wadelius et al.   BLOOD

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

(2008) G. M. Cooper et al.   BLOOD

Pharmacology and Management of the Vitamin K Antagonists

(2008) Jack Ansell et al.   CHEST

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin

(2008) BF Gage et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The V433M Variant of the CYP4F2 Is Associated With Ischemic Stroke in Male Swedes Beyond Its Effect on Blood Pressure

(2008) Cristiano Fava et al.   HYPERTENSION

A Single Nucleotide Polymorphism in the CYP4F2 but not CYP4A11 Gene Is Associated With Increased 20-HETE Excretion and Blood Pressure

(2008) Natalie C. Ward et al.   HYPERTENSION

Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No

(2008) P. M. MANNUCCI et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? Yes

(2008) S. M. THACKER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

γ-glutamyl carboxylase R325Q polymorphism on the response of acenocoumarol

(2008) Rocío González-Conejero et al.   THROMBOSIS RESEARCH